Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer

NCT01964924 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01964924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01964924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
October 2, 2013
Completion date
April 23, 2018
Enrollment
37 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, her2/neu negative, invasive breast carcinoma, progesterone receptor negative, recurrent breast carcinoma, stage iv breast cancer, triple-negative breast carcinoma